Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by M101on Apr 28, 2021 4:33pm
102 Views
Post# 33084914

RE:RE:RE:RE:RBC analyst

RE:RE:RE:RE:RBC analyst
Thenorth1990 wrote: We have seen how it impacted our share price back in November

That's part of the game that Elliot chose to play for personal gain: credit for the winning strategy, finger pointing for the loss, and paid holiday time during any delays.  I don't mind the news vacuum, that's not what causes the share price decline. The price goes down whenever the market knows Elliot is coming to beg and roll over. 
But Elliot's game is probably over as regular pp buyers don't know if there will be any more opportunities to churn stock and expand future holdings at no cost.  So now we have the pundit game where "independent" big pharma lackeys tell us that we are worthless until and unless some big pharma says otherwise. 
Get used to it.  



<< Previous
Bullboard Posts
Next >>